全文获取类型
收费全文 | 483篇 |
免费 | 40篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 106篇 |
口腔科学 | 22篇 |
临床医学 | 39篇 |
内科学 | 77篇 |
皮肤病学 | 4篇 |
神经病学 | 67篇 |
特种医学 | 11篇 |
外科学 | 21篇 |
综合类 | 1篇 |
预防医学 | 25篇 |
眼科学 | 10篇 |
药学 | 27篇 |
肿瘤学 | 70篇 |
出版年
2024年 | 2篇 |
2023年 | 3篇 |
2021年 | 18篇 |
2020年 | 13篇 |
2019年 | 21篇 |
2018年 | 15篇 |
2017年 | 7篇 |
2016年 | 15篇 |
2015年 | 13篇 |
2014年 | 14篇 |
2013年 | 26篇 |
2012年 | 39篇 |
2011年 | 23篇 |
2010年 | 11篇 |
2009年 | 24篇 |
2008年 | 30篇 |
2007年 | 22篇 |
2006年 | 26篇 |
2005年 | 20篇 |
2004年 | 15篇 |
2003年 | 20篇 |
2002年 | 10篇 |
2001年 | 6篇 |
2000年 | 3篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1987年 | 3篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 8篇 |
1978年 | 8篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1973年 | 5篇 |
1967年 | 1篇 |
1965年 | 1篇 |
1964年 | 2篇 |
排序方式: 共有523条查询结果,搜索用时 0 毫秒
11.
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma
Ali Rihani MSc Tom Van Maerken MD PhD Bram De Wilde MD Fjoralba Zeka MSc Geneviève Laureys MD PhD Koen Norga MD PhD Gian Paolo Tonini PhD Simona Coco PhD Rogier Versteeg PhD Rosa Noguera MD PhD Johannes H. Schulte MD PhD Angelika Eggert MD PhD Raymond L. Stallings PhD Frank Speleman PhD Jo Vandesompele PhD 《Pediatric blood & cancer》2014,61(10):1867-1870
12.
Arjan J. Kwakernaak Rob W. van der Pluijm Neelke C. van der Weerd Lianne Koens Wytske M. Westra Krisztina B. Gecse Ankie Kleinjan 《Clinical Case Reports》2022,10(4)
We report a case of intestinal lesions in a patient with a history of lupus nephritis and renal transplantation. Biopsy revealed an EBV‐driven post‐transplant lymphoproliferative disease (PTLD). An EBV‐driven PTLD is a major complication after renal transplantation and is an important differential diagnostic consideration in the follow‐up of renal transplant recipients. 相似文献
13.
van Benten IJ van Drunen CM Koopman LP KleinJan A van Middelkoop BC de Waal L Osterhaus AD Neijens HJ Fokkens WJ 《Journal of medical virology》2003,71(2):290-297
The aim of this study was to investigate potential differences in the local nasal immune response between bronchiolitis and upper respiratory tract infection induced by respiratory syncytial virus (RSV). Nasal brush samples were obtained from 14 infants with RSV bronchiolitis and from 8 infants with RSV upper respiratory tract infection. The samples were taken during infection (acute phase) and 2-4 weeks later (convalescent phase). Cytospin preparations were stained immunohistochemically for T cells, macrophages, and eosinophils. Staining also took place for intercellular adhesion molecule-1 (ICAM-1), T-helper 1 (Th1)-like (interleukin-12 [IL-12], interferon-gamma [IFN-gamma]), Th2-like (IL-4, IL-10), and proinflammatory cytokines (IL-6, IL-8, IL-18). During both RSV-induced bronchiolitis and upper respiratory tract infection, cellular inflammation was observed. This was characterised by an increase in the numbers of nasal macrophages, which tended to be higher in bronchiolitis than in upper respiratory tract infection. Numbers of T lymphocytes and ICAM-1 positive cells increased during both bronchiolitis and upper respiratory tract infection. There were no differences between numbers in the groups. Interestingly, a distinct nasal proinflammatory cytokine response was observed in RSV-induced bronchiolitis. This is characterised by an increase in the number of IL-18 positive cells. This increase is specific for bronchiolitis, as a similar increase could not be detected in RSV-induced upper respiratory tract infection. Numbers of IL-6 and IL-12 positive cells were higher in both bronchiolitis and upper respiratory tract infection, and there were no differences between the groups. By contrast, the number of IL-8, IFN-gamma, IL-4, and IL-10-positive cells remained constant. In conclusion, clear differences were found in nasal immune responses of children with RSV-induced upper respiratory tract infection or bronchiolitis. The induction of a strong IL-18 response was typical for bronchiolitis, as this could not be observed in RSV-induced upper respiratory tract infection, and could explain the eosinophilia that is observed frequently during bronchiolitis. 相似文献
14.
15.
16.
Rondón C Campo P Togias A Fokkens WJ Durham SR Powe DG Mullol J Blanca M 《The Journal of allergy and clinical immunology》2012,129(6):1460-1467
Local allergic rhinitis (LAR) is a localized nasal allergic response in the absence of systemic atopy characterized by local production of specific IgE (sIgE) antibodies, a T(H)2 pattern of mucosal cell infiltration during natural exposure to aeroallergens, and a positive nasal allergen provocation test response with release of inflammatory mediators (tryptase and eosinophil cationic protein). Although the prevalence remains to be established, a number of patients previously given a diagnosis of nonallergic rhinitis or idiopathic rhinitis are now being classified as having LAR. Culprit allergens responsible include house dust mite, grass and olive pollens, and many others. For the diagnosis of LAR, neither skin prick testing nor determination of the presence of serum sIgE antibodies is useful, and a nasal allergen provocation test is needed to identify the culprit allergen or allergens. In a certain proportion of cases, local sIgE can be detected, and conjunctivitis, asthma, or both can be associated. Whether patients with LAR will have systemic atopy in the future is a matter of debate. Further studies are needed for examine the prevalence of this phenomenon in different areas, to improve the diagnostic methods to better identify these patients, and to develop therapeutic approaches, including the use of immunotherapy. 相似文献
17.
Gijs A. Versteeg Ricardo Rajsbaum Maria Teresa Sánchez-Aparicio Ana M. Maestre Julio Valdiviezo Mude Shi Kyung-Soo Inn Ana Fernandez-Sesma Jae Jung Adolfo García-Sastre 《Immunity》2013,38(2):384-398
Highlights? Nearly half of all 75 TRIM protein family members are innate immune enhancers ? TRIM mRNA expression and protein localization are complexly regulated during infection ? TRIMs confer differential regulation in distinct innate immune signaling pathways 相似文献
18.
19.
Michael Selgrad Jan Jacob Koornstra Lucia Fini Marloes Blom Rong Huang Edward B Devol Wytske Boersma-van Ek Gerard Dijkstra Robert C Verdonk Steven de Jong Ajay Goel Sharenda L Williams Richard L Meyer Elizabeth B Haagsma Luigi Ricciardiello C Richard Boland 《Clinical cancer research》2008,14(20):6717-6721
PURPOSE: Liver transplant recepients (LTRs) have an increased risk of colorectal neoplasia. The mechanism responsible for this is unknown. JCV encodes for TAg and has been implicated in colorectal carcinogenesis. We hypothesized that the use of immunosuppression in LTRs facilitates activation of JCV and is responsible for the increased risk of neoplasia. EXPERIMENTAL DESIGN: JCV TAg DNA and protein expression were determined in normal colonic epithelium (n = 15) and adenomatous polyps (n = 26) from LTRs and compared with tissue samples from control patients (normal colon, n = 21; adenomas, n = 40). Apoptosis and proliferation were determined by M30 and Ki-67 immunoreactivity, respectively. RESULTS: JCV TAg DNA was found in 10 of 15 (67%) of normal colonic mucosa from LTRs compared with 5 of 21 (24%) of control normal mucosa (P = 0.025). JCV TAg DNA was detected in 16 of 26 (62%) of the adenomas from LTRs and in 20 of 40 (50%) of control adenomas. JCV TAg protein was expressed in 13 of 26 (50%) adenomas from LTRs versus 2 of 40 (5%) of adenomas from controls (P < 0.001). In adenomas from LTRs, the mean proliferative activity was higher compared with controls (60.3 +/- 3.2% versus 42.7 +/- 2.8%, P < 0.001), whereas mean apoptotic indices were lower in LTRs (0.29 +/- 0.08% versus 0.39 +/- 0.06%, P = 0.05). CONCLUSIONS: The presence of JCV in the colorectal mucosa and adenomas from LTRs, in concert with the use of immunosuppressive agents, suggests that JCV may undergo reactivation, and the subsequent TAg protein expression might explain the increased risk of colorectal neoplasia in LTRs. 相似文献
20.
van Noesel MM van Bezouw S Salomons GS Voûte PA Pieters R Baylin SB Herman JG Versteeg R 《Cancer research》2002,62(7):2157-2161
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces apoptosis in a large variety of cancer cells but not in most normal human cells. This feature makes TRAIL, a potential antitumor agent. TRAIL can bind to four different receptors, two pro-apoptotic death receptors (DRs), DR4 and DR5, and two antiapoptotic decoy receptors (DcRs), DcR1 and DcR2. Normal cells express all four of the receptors. The increased TRAIL sensitivity of tumor cells has been postulated to result from the lack of DcR expression. We studied the tumor-specific down-regulation of the TRAIL receptors DcR1 and DcR2, as well as DR4 and DR5, in a group of pediatric tumor cell lines [nine neuroblastoma and three peripheral primitive neuro-ectodermal tumors (PNETs)] and three cell lines from adult tumors. Lack of expression of DcR1 and DcR2 was widespread (13 of the 15 cell lines and 10 of 15, respectively), both in the adult tumor cell lines and in the pediatric tumor lines. DR4 and DR5 were expressed in 8 of 15 and 12 of 15 cell lines, respectively. To understand the tumor-specific down-regulation of the TRAIL receptors, the promoter regions were studied for possible methylation changes of their CpG islands. All normal tissues were completely unmethylated, whereas in the tumor cell lines, we found frequent hypermethylation of the promoter. For DcR1 and DcR2, we found dense hypermethylation in 9 (69%) of 13 and 9 (90%) of 10 of nonexpressing cell lines, respectively. DR4 and DR5 were methylated in 5 (71%) of 7 and 2 (67%) of 3 nonexpressing cell lines, respectively. Treatment with the demethylating agent 5-aza-2'deoxycytidine resulted in partial demethylation and restored mRNA expression. In addition, we performed mutation analysis of the death domains of DR4 and DR5 by sequencing exon 9. Mutations were not present in any of the neuroblastoma or PNET cell lines. A panel of 28 fresh neuroblastoma tumor samples also lacked expression of DcR1 and DcR2 in 85 and 74% of cases, respectively. Hypermethylation was observed in 6 (21%) of 28 for DcR1 and 7 (25%) of 28 for DcR2. DR4 and DR5 were both expressed in 22 of 28 tumors, and no promoter methylation was observed. These data suggest that hypermethylation of the promoters of DcR1 and DcR2 is important in the down-regulation of expression in neuroblastoma and other tumor types. 相似文献